FASEB SRC on Hematopoietic Malignancies

描述(由申请者提供)：FASE B恶性血液病夏季研究会议是一个高度集中和互动的会议，有致力于血液疾病研究并致力于为患者开发改进疗法的医生和科学家参加。一年一度的美国血液学会会议吸引了超过15,000人参加，与之不同的是，FASEB会议仅限于175人参加，因此为学员与该领域的领导人会面提供了一个合作和支持的环境。2011年会议将重点介绍各种血癌在生物学和治疗方面的最新进展，包括急性髓系白血病、急性淋巴细胞性白血病、骨髓瘤、骨髓增生性肿瘤和骨髓增殖性疾病。此外，今年的会议将包括关于造血系统生物学、干细胞生物学以及代谢突变在血液恶性肿瘤中的作用的会议。我们将举办特别的“会见专家”和“会见编辑”环节，学员可以与该领域的领导者以及《癌症细胞》杂志的编辑海伦娜·杨博士进行一对一的互动。2011年会议的地点将再次是佛蒙特州学院，这是一所位于佛蒙特州乡村的小型寄宿学校。这个网站是一个理想的环境，因为参与者几乎没有分心的事情，而且可以全天与学生和博士后互动。会议将强调以下关键领域：1)肿瘤代谢物的鉴定及其对血癌治疗和诊断的影响；2)正常的造血干细胞和祖细胞发育以了解白血病干细胞(LSC)生物学；3)造血肿瘤转录调控变化的机制，特别是DNA甲基化以及组蛋白乙酰化、甲基化和染色质结构的变化；4)microRNAs在CLL发病机制和作为癌症生物标志物中的作用；5)从动物模型的使用中吸取的教训；LSC的鉴定和抗LSC疗法；6)人类基因组计划在血液恶性肿瘤研究中的影响，重点是功能基因组学；7)系统生物学方法在血液系统恶性肿瘤和LSC生物学中的应用；8)基于对疾病的分子理解的最新治疗进展；例如T-ALL中的Notch抑制剂；慢性髓系白血病中格列卫耐药和敏感性的机制；APL和CLL中三氧化二砷的使用；以及在骨髓增生性肿瘤中使用JAK抑制剂的努力。来自国家卫生研究院的支持将用于为受训人员和早期调查人员以及一小部分受邀演讲者提供登记和住宿。 公共卫生相关性：尽管在治疗少数亚型血液恶性肿瘤方面取得了重大突破，例如格列卫在慢性髓系白血病中的应用，但大多数血癌仍然是成人和儿童患者发病率和死亡率的主要原因。FASE B血液系统恶性疾病夏季研究会议旨在将基础研究人员、翻译研究人员和临床研究人员聚集在一起，就最新发现进行有见地和富有成效的交流。会议还促进了在这一重要研究领域的新的合作和对研究生、博士后研究员和早期研究人员的培训。

DESCRIPTION (provided by applicant): The FASEB Summer Research Conference on Hematopoietic Malignancies is a highly focused and interactive meeting of physicians and scientists who are dedicated to the study of blood diseases and are committed to developing improved therapies for patients. Unlike the annual American Society of Hematology Meeting, which draws well over 15,000 participants, the FASEB meeting, is restricted to 175 attendees and thus provides a collaborative and supportive environment for trainees to meet with leaders in the field. The 2011 meeting will highlight recent advances in biology and treatment of a wide spectrum of blood cancers, including acute myeloid leukemia, acute lymphoid leukemia, myeloma, myeloproliferative neoplasms and myeloproliferative diseases. In addition, this year's meeting will include sessions on systems biology of hematopoiesis, stem cell biology, and the role of metabolic mutations in hematologic malignancies. We will hold special "Meet the Expert" and "Meet the Editor" sessions, where trainees can interact one on one with leaders in the field and with Dr. Helena Yang, editor of the journal Cancer Cell. The site of the 2011 meeting will once again be the Vermont Academy, a small boarding school in rural Vermont. This site is an ideal setting, because the participants have few distractions and are available to interact with students and post-docs throughout the day. The meeting will emphasize the following key areas: 1) The identification of oncometabolites and their implications for blood cancer treatment and diagnosis; 2) Normal hematopoietic stem and progenitor cell development for understanding leukemia stem cell (LSC) biology; 3) Mechanisms of altered transcriptional regulation in hematopoietic neoplasms, with a particular focus on changes in DNA methylation as well as histone acetylation, methylation and chromatin structure; 4) Role of microRNAs in CLL pathogenesis and as cancer biomarkers; 5) Lessons learned from the use of animal models; identification of LSCs and anti- LSC therapies; 6) The impact of the human genome project in investigations of hematological malignancies, with an emphasis on functional genomics; 7) Application of systems biology approaches to hematopoietic malignancies and LSC biology; and 8) Recent therapeutic advances based on a molecular understanding of the diseases; e.g. Notch inhibitors in T-ALL; mechanisms of Gleevec resistance and sensitivity in chronic myeloid leukemia, use of arsenic trioxide in APL and CLL, and efforts to utilize JAK inhibitors in myeloproliferative neoplasms. Support from the NIH will be used to provide registration and lodging for trainees and early stage investigators and a small subset of invited speakers. PUBLIC HEALTH RELEVANCE: Although there have been major breakthroughs in treating a few subtypes of hematologic malignancies, such as the use of Gleevec in chronic myeloid leukemia, the majority of blood cancers remain major causes of morbidity and mortality of both adult and pediatric patients. The FASEB Summer Research Conference on Hematopoietic Malignancies serves to bring together basic, translational, and clinical researchers for an insightful and productive exchange of latest discoveries. The meeting also fosters new collaborations and the training of graduate students, post---doctoral fellows and early stage investigators in this important research field.